Endocrine Abstracts

Background: In male to female transgender patients breast development is a key part in the process of feminization using cross sex hormone therapy. In the Endocrine Society’s clinical guideline ‘Endocrine treatment of transsexual persons’ the onset of breast growth is estimated as 3–6 months after starting cross sex hormone treatment. The maximum breast growth however is seen after 2–3 years. But how much growth, in centimeters or cup-sizes, we can exp...

Introduction: Fat distribution is an important secondary sex characteristic, which is generally peripherally or pear-shaped (gynoid) in females and centrally or apple-shaped (android) in males. Total body fat increases in male-to-females (MtFs) and decreases in female-to-males (FtMs) during cross-sex hormone therapy (CSHT), approaching body fat amounts of the desired sex. However, changes in android or gynoid fat distribution might be a better measure for masculinization and f...

Background: Sex steroids probably stimulate growth-hormone secretion during puberty, which in turn contributes to the development of gender specific body characteristics. Hypothetically, adequate growth hormone levels in transgender persons are also important to achieve the best therapeutic results. The influence of cross-sex hormone treatment (CHT) at growth-hormone production in adult transgender persons is not yet elucidated.Objective: To investigate ...

Introduction: Cross-sex hormone therapy is part of the treatment of individuals with gender dysphoria and affects several factors such as body composition and thereby cardiovascular risk. However, little is known about the specific effects on body weight and fat percentage in the first year of treatment.Aim: The aim of this study is to examine the effects of cross-sex hormones on body weight and total fat percentage during the first year of treatment.</p...

Introduction: Gender dysphoria refers to the incongruence between the subject’s experienced sex on the one hand and the assigned sex on the other hand. Several studies assume a relationship between oestrogen substitution therapy and serum prolactin levels.Aim: The aim of this study is to get more insight into the effect and time-course of changes in serum prolactin levels during cross-sex hormone therapy.Methods: This prospect...